Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adi Vaknin-Dembinsky

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Archives of Neurology|October 13, 2010
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosisDimitrios Karussis, Clementine Karageorgiou, Adi Vaknin-Dembinsky, et al.
International Immunopharmacology|March 18, 2020
RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammationYael Ben-David, Sara Kagan, Hagit Cohen Ben-Ami, et al.
Journal of the Neurological Sciences|December 7, 2021
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stageShay Menascu, Aviva Fattal-Valevski, Adi Vaknin-Dembinsky, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 25, 2026
Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategiesLior Fuchs, Ifat Vigiser, Hadar Kolb, et al.
Plos One|December 29, 2012
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trialDimitrios Karussis, Hagai Shor, Julia Yachnin, et al.
Multiple Sclerosis and Related Disorders|July 25, 2025
Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onsetNanthaya Tisavipat, Adi Wilf-Yarkoni, Abdullah Al-Ani, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 31, 2023
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and SatralizumabFriedemann Paul, Romain Marignier, Jacqueline Palace, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2016
Identification of tissue-specific cell death using methylation patterns of circulating DNARoni Lehmann-Werman, Daniel Neiman, Hai Zemmour, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2022
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, et al.
Annals of Clinical and Translational Neurology|August 5, 2024
Application of the international criteria for optic neuritis in the Acute Optic Neuritis NetworkPhilipp Klyscz, Susanna Asseyer, Ricardo Alonso, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Archives of Neurology|October 13, 2010
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosisDimitrios Karussis, Clementine Karageorgiou, Adi Vaknin-Dembinsky, et al.
International Immunopharmacology|March 18, 2020
RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammationYael Ben-David, Sara Kagan, Hagit Cohen Ben-Ami, et al.
Journal of the Neurological Sciences|December 7, 2021
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stageShay Menascu, Aviva Fattal-Valevski, Adi Vaknin-Dembinsky, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 25, 2026
Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategiesLior Fuchs, Ifat Vigiser, Hadar Kolb, et al.
Plos One|December 29, 2012
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trialDimitrios Karussis, Hagai Shor, Julia Yachnin, et al.
Multiple Sclerosis and Related Disorders|July 25, 2025
Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onsetNanthaya Tisavipat, Adi Wilf-Yarkoni, Abdullah Al-Ani, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 31, 2023
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and SatralizumabFriedemann Paul, Romain Marignier, Jacqueline Palace, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2016
Identification of tissue-specific cell death using methylation patterns of circulating DNARoni Lehmann-Werman, Daniel Neiman, Hai Zemmour, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2022
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, et al.
Annals of Clinical and Translational Neurology|August 5, 2024
Application of the international criteria for optic neuritis in the Acute Optic Neuritis NetworkPhilipp Klyscz, Susanna Asseyer, Ricardo Alonso, et al.
Pageof 10